Akanda Corp (NASDAQ: AKAN) (FRA: Y232) shares slid hard after Fugazi Research released its critical short report on May 4. AKAN stock dropped more than 32 per cent in one trading session.
Investors took notice of the report’s claims that the company suffers from extreme dilution risks, negligible operations and no fundamental value overall.
Fugazi Research detailed a troubling picture in its writings. The firm noted that only about 534,000 shares are currently available to trade after a reverse split while more than 6.7 million additional shares are already registered and can be sold into the market at any time. It highlighted “toxic” convertible notes that convert at deep discounts and drive repeated dilution.
Akanda shut down its primary UK cannabis subsidiary in March last year. Unaudited 2025 revenue reached only about US$258,000 against nearly US$4.8 million in operating expenses. The company is now relying on a modest Mexican fibre infrastructure contract worth around US$200,000 per year to sustain itself.
Essentially, Fugazi described the shares as non-investable with zero fundamental value. Its writers cited high debt, ongoing cash burn, going-concern warnings and a long history of reverse splits to draw this conclusion.
This sharp decline followed a dramatic rally fuelled by Trump administration moves on cannabis rescheduling. In late April, positive news about shifting marijuana toward Schedule III triggered a broad sector surge. Akanda subsequently climbed by more than 200 per cent in a single session, which was significantly attributable to its small float. Other stocks like Canopy Growth Corp (TSE: WEED) (NASDAQ: CGC) (FRA: 11L) and Tilray Brands Inc (TSE: TLRY) (NASDAQ: TLRY) (FRA: 2HQ) saw considerable market gains at the time too.
The Fugazi report has now ended that hype by exposing the wide gap between policy optimism and the company’s actual business reality.
Led by financial researcher David Capablanca, Fugazi focuses on activist short selling. The firm targets companies with questionable financial structures, heavy promotion and weak fundamentals. It has built a solid track record of publishing reports that lead to meaningful stock declines.
Akanda originally positioned itself as an international medical cannabis cultivator, manufacturer and distributor. It went public on the Nasdaq in 2022 but never scaled up to a commercial level. The company later pivoted toward Mexican telecom infrastructure through an acquisition even as older materials and its website still reference cannabis roots.
Independent Substack writer The M&A Hunter flagged similar risks on April 30, calling Akanda’s capital structure one of the worst he had catalogued due to stacked convertibles, reverse splits and promotion tactics. His pre-report analysis adds credibility as an independent voice that identified the same structural problems.
The core concerns in the Fugazi report appear largely valid. Public SEC filings back the key points on dilution, revenue collapse, rising debt and the business pivot.
Akanda Corp has not publicly addressed the concerns voiced by Fugazi’s critical write up.
We just published a short report on $AKAN
A Half-Baked Cannabis Company Where Shareholders get Smoked
6 reverse splits in 3 years, less than 260k in revenue, and not ONE single dollar from weed revenue since February 2025
Full report ⬇️https://t.co/IkewxtfGjz pic.twitter.com/pwVTOVE1k8
— Fugazi Research (@FugaziResearch) May 4, 2026
Read more: Cannabis stocks swing wildly on U.S. rescheduling news
Follow Rowan Dunne on LinkedIn
rowan@mugglehead.com
